Abstract
This work presents the status, in Brazil, of pharmaceutical patents granted by US Patent and Trademark Office (USPTO) and their role on the Brazilian Pharmaceutical market. Data show that 27.1% of the US-granted patents filed in Brazil are granted by Instituto Nacional da Propriedade Industrial (INPI) and 76.5% of them have their term extended due to provision of article 40 of the Brazilian Industrial Property Law (LPI 9279/96), while 65% of these US-patents are not valid in Brazil, evidencing market openness and independence of patent examination of INPI before USPTO. The effects of INPI backlog of patent examination on pharmaceutical market are also highlighted. These aspects are relevant to stablish better strategies to reduce backlog and to orient public policies to stimulate the Brazilian industry, especially with respect to the production of generic and similar drugs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
